BioCentury
ARTICLE | Company News

Antisense Therapeutics, Cortendo deal

May 25, 2015 7:00 AM UTC

Antisense granted Cortendo exclusive rights to develop and commercialize ATL1103 for endocrinology indications. Antisense will receive $5 million up front and is eligible for up to $105 million in development and commercialization milestones, plus royalties. Cortendo will fund manufacturing, regulatory and developmental costs for the second-generation antisense inhibitor of growth hormone receptor (GHr), which is in Phase II testing to treat acromegaly. ...